PCSK9 Inhibitors

PCSK9 inhibitors are a type of medication used to lower LDL cholesterol, often referred to as "bad cholesterol." They work by targeting a protein in the body called PCSK9 (short for proprotein convertase subtilisin/kexin type 9), which plays a key role in regulating cholesterol levels in the blood.

Under normal circumstances, your liver has special receptors that remove LDL cholesterol from the bloodstream. However, PCSK9 can bind to these receptors and cause them to break down, meaning fewer receptors are available to clear LDL cholesterol. As a result, more cholesterol stays in the blood.

PCSK9 inhibitors are monoclonal antibodies, and are lab-made proteins designed to block the PCSK9 protein. By inhibiting PCSK9, these drugs allow more LDL receptors to stay active on liver cells. This helps the liver remove more LDL cholesterol from the blood, leading to significantly lower cholesterol levels.

These medications are especially helpful for people who have familial hypercholesterolemia (a genetic condition that causes very high cholesterol), or for those who are at high risk for heart disease and haven’t reached their cholesterol goals with statins alone. PCSK9 inhibitors are given by injection, usually every 2–4 weeks.

In clinical trials, they've been shown not only to reduce LDL levels but also to lower the risk of heart attacks and strokes in high-risk individuals. They're a powerful tool in modern cardiovascular care, especially for patients who need more aggressive cholesterol management.